[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"diabetes-gestational\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:diabetes-gestational":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,65,99,125,151,182],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":45,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":64},"100634052","early-pregnancy-lifestyle-and-glucose-patterns-a-substudy-of-tofffy-100634052",false,"NCT07534670","Early Pregnancy Lifestyle and Glucose Patterns: A Substudy of TOFFFY","Early-Pregnancy Chronobehavioural Profiles and Continuous Glucose Dynamics: A Nested Randomised Pilot Study of TOFFFY","Inclusion Criteria:\n\n* Enrolled in the Towards Optimal Fertility, Fathering and Fatherhood studY (TOFFFY) (NCT06293235)\n* Females who are currently pregnant and with viable intrauterine pregnancy at ≤13 weeks gestation at enrolment\n\nExclusion Criteria:\n\n* Females with pre-existing diabetes mellitus (Type 1 or Type 2) and\u002For chronic medical conditions affecting glucose metabolism\n* Females who are taking medications known to significantly affect glucose metabolism\n* Females with multiple pregnancy (e.g., twins or higher-order gestation)\n* Females who are unable to comply with study procedures, including: Inability to use smartphone-based applications and inability to wear wrist actigraphy device",true,"FEMALE","21 Years","39 Years",{"count":21,"type":22},140,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to examine how daily behavioral patterns in early pregnancy, including sleep, physical activity, and meal timing, influence continuous glucose dynamics and subsequent risk of gestational diabetes mellitus (GDM) in pregnant women without pre-existing diabetes.\n\nThe main questions it aims to answer are:\n\n1. Do early-pregnancy chronobehavioral patterns (e.g., irregular sleep, night eating, and unstable rest-activity rhythms) relate to continuous glucose patterns measured using continuous glucose monitoring (CGM)?\n2. Can early behavioral and CGM-derived measures predict glucose regulation and metabolic outcomes later in pregnancy (24-28 weeks)?\n3. Does real-time self-monitoring using wearable devices and food logging improve glycemic outcomes compared to usual care?\n\nThis study is a prospective, nested randomized pilot trial embedded within the ongoing Towards Optimal Fertility, Fathering and Fatherhood studY (TOFFFY) cohort (NCT06293235) at KK Women's and Children's Hospital, Singapore. A total of 140 pregnant women without pre-existing diabetes, recruited at ≤13 weeks gestation, will be randomized in a 1:1 ratio to either a pilot arm (wearable-based self-monitoring) or a control arm (usual care).\n\nParticipants in the pilot arm (n=70) will undergo intensive behavioral and metabolic monitoring over a 14-day period in early pregnancy, including continuous glucose monitoring using a CGM device, wrist actigraphy to assess sleep-wake and rest-activity patterns, and an AI-supported mobile application to record meal timing and dietary intake. Participants will have real-time access to their glucose data and behavioral feedback, enabling self-monitoring and potential behavioral adjustments.",[28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44],"Continuous Glucose Monitoring","Diabetes, Gestational","Diet During Pregnancy","Meal Time","Actigraphy","Pregnancy","Glucose Intolerance During Pregnancy","Gestational Diabetes Mellitus in Pregnancy","Circadian Rhythm","Sleep","Chronobiology","Wearable Electronic Devices","Mobile Applications","Blood Glucose Profile","Metabolic Diseases","Randomized Controlled Trial","Pilot Study",[46,47,48,49,50,51],"Risk factor","Lifestyle","Early pregnancy","Chrono-disruptive behaviours","Maternal health","Lifestyle intervention","NOT_YET_RECRUITING","2026-04-22",{"date":55,"type":56},"2026-04-27","ACTUAL",{"date":58,"type":22},"2026-05-01",{"date":60,"type":22},"2027-06-30",{"name":62,"class":63},"KK Women's and Children's Hospital","OTHER_GOV",1,{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":17,"minAge":72,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":23,"phases":75,"briefSummary":76,"conditions":77,"keywords":80,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":64},"100628235","usability-evaluation-of-gen-ai-based-nutrition-chatbot-for-pregnant-women-100628235","NCT07458997","Usability Evaluation of Gen AI-based Nutrition Chatbot for Pregnant Women","Usability Evaluation of Gen AI-based Nutrition Chatbot for Pregnant Women: A Pilot Quasi-experimental Study","Inclusion Criteria:\n\n* Pregnant women aged 18 years or older\n* Able to provide informed consent in the study language\n* Own a smartphone with internet access and the WeChat application\n\nExclusion Criteria:\n\n* Current enrollment in other nutrition intervention studies\n* Severe mental health conditions that may impair technology use or ability to provide informed consent","18 Years",{"count":74,"type":22},100,[25],"Background: Pregnancy imposes significant physical demands, with complications like gestational diabetes (GDM) and pre-eclampsia posing serious risks. Nutrition is crucial for mitigation, but accessing reliable guidance remains challenging. This study evaluates the feasibility of an AI chatbot providing nutritional guidance for managing these conditions.\n\nMethods: In a quasi-experimental design, 100 pregnant women will self-select into either the intervention group (n=50, using an AI chatbot) or control group (n=50, receiving standard care). The primary outcome is usability measured by the System Usability Scale (SUS) at 12 weeks, with an expected mean difference of ≥13 points. Secondary outcomes include technology acceptance (Technology Acceptance Model), user engagement, information accuracy, and changes in dietary knowledge\u002Fbehaviors. Quantitative data will be analyzed using intention-to-treat and t-tests. Semi-structured interviews with 20 participants will explore user experiences through thematic analysis.\n\nExpected Results: The AI chatbot is anticipated to demonstrate superior usability and high user acceptance (TAM \\>5.0\u002F7), with improvements in dietary knowledge and behavior. Qualitative findings will provide insights into benefits, barriers, and engagement factors.\n\nConclusion: This study will establish an evidence base on AI chatbot feasibility and acceptance for prenatal nutrition, informing tool optimization and future large-scale trials.",[29,78,79],"Pre-eclampsia","AI Chatbot for Prenatal Nutrition Guidance",[81,82,83,84,85,86,87,88],"AI chatbot","prenatal nutrition","gestational diabetes","pre-eclampsia","feasibility","usability","technology acceptance","mixed methods","2026-03-04",{"date":91,"type":56},"2026-03-09",{"date":93,"type":22},"2026-06-01",{"date":95,"type":22},"2027-01-31",{"name":97,"class":98},"Hong Kong Metropolitan University","OTHER",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":72,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":23,"phases":109,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":64},"100538509","gestational-diabetes-after-gastric-bypass-surgery-100538509","NCT06291766","Gestational Diabetes After Gastric Bypass Surgery","The Impact of Continous Glucose Monitoring on Pregnancy Outcome, in Women With Gestational Diabetes and a History of Gastric Bypass Surgery.","Inclusion Criteria:\n\n* Understands written and spoken Swedish\n* Previous Gastric Bypass surgery\n* Diagnosed with gestational diabetes according to our local criteria\n* Planned follow up at the Specialized Maternity Ward at Skane University Hospital\n* Understands the use of CGM and is willing to use the system\n* Have signed informed consent\n\nExclusion Criteria:\n\n* Other kinds of bariatric surgery","50 Years",{"count":108,"type":22},120,[25],"The goal of this trial is to compare different means of glucose monitoring in women with gestational diabetes and a history of gastric bypass surgery.\n\nThe main question it aims to answer is:\n\nHow does continous glucose monitoring impact the treatment and affect pregnancy outcome in these women.\n\nParticipants will be randomized to either continous glucose monitoring or regular capillary glucose measurements during the last trimester of their pregnancy. Researchers will compare the glucose measurement outcomes, the glucose lowering treatment given and pregnancy outcomes between groups.",[29,112,113,114],"Gastric Bypass Status for Obesity Complicating Pregnancy, Childbirth, or the Puerperium","Pregnancy in Diabetic","Blood Glucose Self Monitoring","RECRUITING","2025-08-18",{"date":118,"type":56},"2025-08-22",{"date":120,"type":56},"2024-01-01",{"date":122,"type":22},"2035-12",{"name":124,"class":98},"Region Skane",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":133,"minAge":72,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":136,"phases":4,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":150},"100549726","exploration-of-health-literacy-in-diabetes-in-reunion-island-and-france-100549726","NCT06437782","Exploration of Health Literacy in Diabetes in Reunion Island and France","Exploration of Health Literacy in Diabetes in Reunion Island and Metropolitan France","HLQ-Diabete","Inclusion Criteria:\n\nPatient with type 1, 2 or gestational diabetes taken care in hospital\n\nExclusion Criteria:\n\n* Patient unable to understand and respect study procedures\n* Patient with cognitive disorder\n* Patient with serious acute complication due to diabetes within 15 days before inclusion\n* Stroke history with neurologic consequences\n* Other specific types of diabetes : chronic calcific pancreatitis, iatrogenic, other secondary diabetes, rare monogenic or genetic diabetes due to insulin resistance","ALL",{"count":135,"type":22},1350,"OBSERVATIONAL","The goal of this observational study is to identify the health literacy profile of diabetic patients in Reunion Island and France in order to obtain information to improve access to information, therapeutic education and to health service. The main question\\[s\\] it aims to answer \\[is\u002Fare\\]:\n\nParticipants will complete the Health Literacy Questionnaire (HLQ) once.",[139,140,29],"Diabetes type1","Diabetes Type 2","2025-07-28",{"date":143,"type":56},"2025-07-30",{"date":145,"type":56},"2025-04-17",{"date":147,"type":22},"2026-06",{"name":149,"class":98},"Centre Hospitalier Universitaire de la Réunion",2,{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":17,"minAge":72,"maxAge":159,"enrollmentInfo":160,"targetDuration":4,"studyType":23,"phases":162,"briefSummary":165,"conditions":166,"keywords":169,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":181},"100557259","phase-2-inhaled-insulin-vs-rapid-acting-injections-for-post-meal-glucose-control-in-women-with-gestational-diabetes-100557259","NCT06535789","Inhaled Insulin vs Rapid-acting Injections for Post-meal Glucose Control in Women With Gestational Diabetes","The Safety and Efficacy of Rapid Acting Inhaled Technosphere Insulin (Afrezza) Compared With Subcutaneous Insulin to Achieve Pregnancy-Specific Postprandial Targets Among Patients With Gestational Diabetes","INHALE-GDM","Inclusion Criteria\n\n1. Ability to provide informed consent for study participation\n2. Age ≥18 years and \\\u003C41 years old\n3. Singleton pregnancy at 24-34 weeks gestation\n4. Diagnosis of GDM via standard 1-step or 2-step criteria\n5. Treated with an insulin regimen that includes a RAA bolus of any type for breakfast, with a dose \\\u003C20 units\n6. Pre-pregnancy or first trimester body mass index (BMI) 25-45\n7. Investigator believes that the protocol can be safely conducted by the participant\n8. Able to read and speak English\n\nExclusion Criteria\n\n1. Type 1 diabetes or type 2 diabetes\n2. HbA1c ≥ 6.5%, FBG ≥125 mg\u002Fdl or 2-hr glucose ≥200 mg\u002FdL on 75g OGTT, or random plasma glucose ≥200 mg\u002FdL (consistent with pre-existing diabetes and not GDM diagnosis)\n3. Current use of any non-insulin glucose lowering medication\n4. Using TI (Afrezza), regular insulin, or ≥20 RAA units at breakfast (NPH is permissible)\n5. Peak expiratory flow \\\u003C80% predicted as measured by peak flow meter\n6. Recent history of asthma (defined as using any medications to treat asthma within the last year), chronic obstructive pulmonary disease (COPD), or any other clinically important pulmonary disease (e.g., cystic fibrosis or bronchopulmonary dysplasia), or significant congenital or acquired cardiopulmonary disease as judged by the Investigator\n7. Smoking (includes cigarettes, cigars, pipes, and\u002For vaping devices) within 90 days prior to screening\n8. History or current diagnosis of lung cancer\n9. Current or anticipated use of oral, inhaled or injectable glucocorticoids during the time period of the trial (topical glucocorticoid use is acceptable)\n10. Renal or hepatic impairment that in the investigator's judgment poses a safety risk for the study participant\n11. Recurrent Level 2 (blood glucose \\\u003C54 mg\u002FdL) or Level 3 severe hypoglycemia events\n12. Current use of non-cardio-selective beta blockers\n13. Being a member of the study team, having a direct supervisor at place of employment who is also directly involved in conducting the clinical trial (as a study Investigator, coordinator, etc.); or having a first-degree relative who is directly involved in conducting the clinical trial","40 Years",{"count":161,"type":22},30,[163,164],"PHASE2","PHASE3","Pregnant women aged 18-40 with gestational diabetes (GDM) will take part in this study. We want to see how two different insulin treatments affect their blood sugar after they eat. These women usually use a rapid-acting insulin analog (RAA) that's injected to control their blood sugar before and after meals. They will come to the clinic for two meal sessions. For the first meal, we will randomly decide if they will use the usual RAA insulin or a newer inhaled insulin called technosphere insulin (TI). They will use the other type of insulin for their second meal. After each meal, we will compare their blood sugar levels.",[29,167,168,34],"Pregnancy Complications","Glucose Metabolism Disorders",[170,171],"Gestational Diabetes","Inhaled Insulin","2025-05-13",{"date":174,"type":56},"2025-05-15",{"date":176,"type":22},"2025-05",{"date":178,"type":22},"2025-07",{"name":180,"class":98},"Jaeb Center for Health Research",5,{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":17,"minAge":72,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":23,"phases":191,"briefSummary":192,"conditions":193,"keywords":194,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":64},"100503840","effect-of-strength-resistance-exercise-in-the-reduction-of-gestational-diabetes-in-pregnant-women-with-overweight-or-obesity-100503840","NCT05840497","Effect of Strength-resistance Exercise in the Reduction of Gestational Diabetes in Pregnant Women with Overweight or Obesity","Efecto Del Ejercicio De Fuerza-resistencia En La Disminución De La Diabetes Gestacional En Gestantes Con Sobrepeso U Obesidad","Inclusion Criteria:\n\n* BMI≥25 kg\u002Fm2\n* Singleton pregnancies\n\nExclusion Criteria:\n\n* Chronic hypertension\n* Pre-pregnancy DM (type I or 2 diabetes mellitus)\n* Cardiovascular disease\n* History of preterm delivery",{"count":190,"type":22},200,[25],"The aim of this trial is to test the efficacy of regular resistance exercise in early pregnancy to prevent gestational diabetes mellitus in overweight\u002F obese pregnant women.",[29],[195,196,197,198,199],"Exercise","Weight gain","Pregnant","Obese","Overweight","2024-11-20",{"date":202,"type":56},"2024-11-22",{"date":204,"type":56},"2023-03-01",{"date":206,"type":22},"2025-09-30",{"name":208,"class":98},"Fundacion Miguel Servet"]